Please Note:
This profile was automatically generated using 67 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 67 references found on the Internet. This information has not been verified. Learn more...
View all 67 references Web References
-
1. Harvard Medical School Genetics Training Program
www.hpcgg.org/GeneticsTraining - [Cached]Published on: 8/25/2008 Last Visited: 8/25/2008
Harvey Levy, Ph.D. , is co-director of the HMS ABMG Clinical Biochemical Genetics program.Dr. Levy specializes in biochemical genetics (metabolism).He is Senior Associate in Medicine/Genetics at Children's Hospital Boston and Professor of Pediatrics at the Harvard Medical School.He was formerly Director of the Metabolic Program and currently serves as an attending physician within the program.Dr. Levy conducts clinical research in two areas of metabolism, phenylketonuria (PKU) and clinical and biochemical follow-up of newborn screening for metabolic disorders.He has very active research projects ongoing in those areas. -
2. BIOMARIN PHARMACEUTICAL INC. - Investors - Press Release
phx.corporate-ir.net/phoenix.z - [Cached]Published on: 8/31/2007 Last Visited: 9/3/2007
Harvey Levy, M.D., Associate Professor, Harvard Medical School, Boston, Massachusetts; Director, Maternal PKU Program, Children's Hospital, Boston, Massachusetts; Recipient of the Allen C. Crocker Award from the New England Genetics Group; Contributor, NIH Consensus Statement on PKU: Screening and Management -
3. Researchers testing medicines for deadly, debilitating genetic diseases - The Clarion-Ledger
www.clarionledger.com/apps/pbc - [Cached]Published on: 10/17/2006 Last Visited: 10/18/2006
It is "one of the great stories in genetics" because it showed that genetic diseases can be treated, said Dr. Harvey Levy, director of the Maternal PKU Program at Children's Hospital Boston.
But Levy said the only current treatment is a forbiddingly strict diet: measured amounts of fruit and some vegetables, and a protein drink.
Unfortunately, he said, the pill, called tetrahydrobiopterin or BH4, only worked well in 20 to 30 percent of the people who have tried it in Europe.
But it could help thousands in this country, letting some drop the special diet and others relax it, he said in an earlier interview.

